Status:
COMPLETED
Study of Medical Treatment for Methamphetamine Addiction
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Methamphetamine
Amphetamine Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment ...
Eligibility Criteria
Inclusion
- 18 years of age or older;
- meet DSM-IV criteria for methamphetamine dependence;
- seeking treatment for MA problems;
- specific range of methamphetamine use in the 30 days prior to study entry;
- willing and able to comply with study procedures, including genotyping;
- willing and able to provide written informed consent;
- if female, not pregnant or lactating and willing to use an acceptable method of barrier birth control (e.g. condoms) during the trial.
Exclusion
- have a medical condition that, in the study physician's judgment, may interfere with safe study participation (e.g., active TB, unstable cardiac, renal, or liver disease, unstable diabetes);
- have a current neurological disorder (e.g., organic brain disease, dementia) or major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar disorder) as assessed by the SCID or a medical history which would make study agent compliance difficult or which would compromise informed consent, or recent (past 30 days) history of suicide attempts and/or current serious suicidal intention or plan as assessed by the SCID;
- currently on prescription medication that is contraindicated for use with bupropion;
- have current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by DSM-IV-TR;
- have a history of alcohol dependence within the past three years;
- have a history of a seizure disorder;
- have a medical condition (such as serious head injury) that is associated with increased risk of seizures or on a medication that lowers the seizure threshold;
- have a history of anorexia or bulimia;
- have current hypertension uncontrolled by medication, or any other circumstances that, in the opinion of the investigators, would compromise participant safety;
- have a history of sensitivity to bupropion.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00833443
Start Date
January 1 2009
End Date
July 1 2013
Last Update
February 26 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Clinical Research Site 910 Vine St
Los Angeles, California, United States, 90038